Replies to post #12032 on Naz News, Gappers and FLE's

[mcmike]

FLASH MEMORY SNDK FLSH SFUN SSTI LEXR

exited a long term holding in FLSH for a 50% gain
sold 1/4 SNDK: free shares orignallly purchased at 18 (pre-split)

received 0 shares from allocation of SFUN, new Israeli fabless flash memory technology co. Then missed the walkdown and turnaround at 28. may buy some in the a.m. ... a partial or starter position.

http://stockcharts.com/candleglance/?SNDK,FLSH,SSTI,LEXR,SFUN|D|P14,3,3

[iconoclassic]

mike, your BSX news...Boston Scientific Announces Start of Clinical Trial Assessing Precision(R) Spinal Cord Stimulator for Treatment of Migraine Headaches
Thursday November 10, 8:30 am ET
Pivotal study to assess occipital nerve stimulation using the Precision(R) implantable neurostimulator as a treatment for refractory migraine headache


NATICK, Mass., Nov. 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX - News) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to begin a prospective, randomized, double-blind pivotal trial to evaluate the safety and efficacy of occipital nerve stimulation as a treatment for refractory migraine headache. The study, known as PRISM (PRecision Implantable Stimulator for Migraine), will use Boston Scientific's Precision neurostimulator and involve approximately 150 patients at up to 15 sites in the U.S.
ADVERTISEMENT


The Precision device is the smallest rechargeable neurostimulator on the market today and is already approved by the FDA for spinal cord stimulation to treat chronic pain. In the PRISM study, the Precision neurostimulator will be used to deliver electrical impulses to the occipital nerves located just under the skin at the back of the neck. Occipital nerve stimulation is intended to treat migraine headache in patients who do not respond to other therapies. There are more than 28 million migraine sufferers in the U.S. and up to 10 percent of these patients may not respond to existing treatments.

"Occipital nerve stimulation has the potential to provide relief to the large population of refractory migraine sufferers who currently have no other medical treatments available to them," said Dr. David Biondi, Director of the Headache Management Program at Spaulding Rehabilitation Hospital in Boston and Instructor of Neurology at Harvard Medical School. "If effective, the Precision implantable neurostimulator would provide a new treatment option to free these patients from their long-standing headache pain."

"As the smallest rechargeable neurostimulator available, our Precision device represents a best-in-class neuromodulation technology that has treated more than 2,000 patients suffering from chronic pain," said Jeffrey H. Greiner, President of Boston Scientific's Neuromodulation Group. "We are excited about the prospect of extending this same advanced technology to address the unmet needs of migraine sufferers."

About the Precision® Implantable Neurostimulator

The Precision neurostimulator is currently FDA approved and marketed for spinal cord stimulation to treat chronic pain by precisely delivering tiny electrical signals to the spinal cord that mask the perception of pain. Spinal cord stimulation is prescribed for patients with chronic pain in the limbs, trunk and back. Patients interested in learning more can visit http://www.ControlYourPain.com.

About Boston Scientific Corporation

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. Boston Scientific's Neuromodulation Group is a global leader in the development of implantable, high-technology neurostimulation devices that include new treatments for deafness and chronic pain. For more information, please visit http://www.bostonscientific.com and http://www.advancedbionics.com.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.



CONTACT: Milan Kofol
508-650-8569
Investor Relations
Boston Scientific Corporation

Paul Donovan
508-650-8541
Media Relations
Boston Scientific Corporation




--------------------------------------------------------------------------------
Source: Boston Scientific Corporation

[mcmike]

SRDX news: SurModics' Hydrophilic Coating on Medtronic Endeavor(TM) Drug-Eluting Stent Delivery System

http://www.knobias.com/individual/public/news.htm?eid=3.1.4b64503469a6333a716779d5e2066c873abb97b522....

This is not the coating in which the drug that eludes from the stent is encased...

This is a coating that increases the slipperiness...lubricity of the catheter used to insert the stent into the relevant arteries.

"our Hydrophilic Technologies business unit offers advanced lubricity, hydrophilic coatings on DES delivery catheters."

[mcmike]

STJ a study in trading via stochastics:



buy crossing up from oversold
sell down from overbought

entry point: clearing $40 previous resistance from 2004 after the retreat from the high near 43 and pullback to 34.48 (a conservative entry giving up a $5 swingtrade).

 date  entry  inprice outprice gain/loss 
 05/16 long  38.54 40.80 2.26 
 05/27 short 40.80 39.62 1.18 
 06/14 long  40.36 44.25 3.89 
 07/13 short 44.25 43.75 0.50 
 07/18 long  43.75 47.16 3.41 
 08/01 short 47.16 43.99 3.17 
 08/25 long  44.03 47.23 3.20 
 09/12 short 47.26 46.09 1.17 
 10/14 long  45.00 47.99 2.99 
 10/26 short 47.99 48.43 -.44 
 11/23 short 49.07 48.60 0.47 
 12/02 long  48.78 53.40 4.62 
 01/17 short 53.37

buy hold          +14.83 +38%  
 buy oversold      +20.37 +53% - 10 commissions 
 buy 100 long,  
 cover & short 100 +26.42 +69% - 24 commissions